Loading market dashboard
Ginkgo Bioworks Holdings, Inc.
DNAHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BOULDER, Colo.--(BUSINESS WIRE)-- #ArcherAnalysis--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648.
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventions PLYMOUTH MEETING, Pa., May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia.
Closed sale of the Company's mobile device assets to NEXA in January 2026 Completed the transfer of the operations of the phone and hotspot business to NEXA Focused on enhancing the DNA X trading platform to prepare the platform for its initial growth phase San Diego, California--(Newsfile Corp. - May 20, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the first quarter ended March 31, 2026. The company operates the DNA X AI trading platform business, and expects to launch an enhanced version to the public later this year.
Harmonic's SeaStar Optical Node Enables Cost-Effective Broadband Service Expansion in Previously Underserved Brownfield MDU Environments SAN JOSE, Calif., May 19, 2026 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that DNA Finland, the second largest mobile and fixed broadband operator serving the Finnish market, is expanding multi-gigabit services into lower-density multi-dwelling units (MDUs) with Harmonic's SeaStar™ optical node.
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.
The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (“Lotus Tech” or the “Company”) (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced Focus 2030 for Lotus, an evolved business strategy designed to underpin its competitiveness and transformation into a more flexible and sustainable business model ensuring market resilience amid external headwinds.
Ginkgo Bioworks NYSE: DNA said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter.
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.
Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
Completed acquisition of the DNA X cryptocurrency trading platform Closed sale of the Company's mobile device assets to NEXA in January 2026 Focused on enhancing the DNA X trading platform to prepare the platform for its initial growth phase San Diego, California--(Newsfile Corp. - April 14, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the fourth quarter and full year ended December 31, 2025. The company purchased the DNA X cryptocurrency trading platform business in December 2025, following the launch of the DNA X.us website in November 2025 that is now active.
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) insider Reshma Shetty sold 124,727 shares of the company's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $6.43, for a total value of $801,994.61. Following the completion of the transaction, the insider directly owned 436,422
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) major shareholder Barry Canton sold 13,155 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $6.93, for a total value of $91,164.15. Following the sale, the insider directly owned 351,684 shares in
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) insider Reshma Shetty sold 13,155 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $6.93, for a total value of $91,164.15. Following the completion of the sale, the insider owned 351,684 shares of the company's
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA - Get Free Report) major shareholder Barry Canton sold 13,116 shares of the firm's stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $6.40, for a total transaction of $83,942.40. Following the completion of the sale, the insider owned 338,568
TelevisaUnivision is moving aggressively to turn its microdrama platform into a new growth engine, betting that the melodramatic storytelling that powered decades of telenovelas can be reshaped for mobile-first audiences in one- to two-minute vertical episodes.
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
Elon Musk tweeted about wanting Jurassic Park in real life. Companies aren't bringing back dinosaurs yet, but they are bringing extinct items back to life.
